Celltrion’s Avtozma has been indicated for the treatment of giant cell arteritis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, and COVID-19—in the same dosages and formulations as its tocilizumab reference product.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld value & access advisor for Schoonveld Advisory and author of The Price of Global Health, previews his upcoming February column.
The latest news for pharma industry insiders.
Can monitoring these dispensed Rxs via online search behavior help predict future GLP-1 use in the United States?
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Ed Schoonveld, value & access advisor for Schoonveld Advisory and author of The Price of Global Health, comments on the future implications of the latest CMS drug price negotiations.
The 7,000 square-foot GMP facility will provide formulation development support, along with analytical testing services.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, outlines the technological obstacles that lie ahead for the industry this year.
A study explores dual-enrollment in these plans—compared to other Medicare Advantage plans— impacts North Carolina’s Medicaid fee-for-service spending.
Known as AVT05, the Alvotech medication is a proposed biosimilar to Simponi, prescribed to treat various inflammatory conditions.
The investment not only moves along the company’s efforts in advancing clinical studies, but also opens up 700 new jobs for the Greater Toronto area.
A cross-sectional study investigates the impact of Dobbs v Jackson’s Women’s Health Organization on national support and personal interest.
What factors influence their likelihood of receiving this form of obesity treatment?
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes the importance of the patient within the pharma supply chain.
The latest AARP report concludes that plan members who hit this amount are expected to see savings, even when premiums are considered.
In the fourth part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, discusses the origins of the compounding pharmacy, including what it seeks to accomplish.
Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, explains how collaboration between compounding pharmacies, drug manufacturers, and telehealth platforms can drive success, despite the various litigations pertaining to GLP-1s that are currently taking place.
These medications are used to treat a multitude of conditions including type 2 diabetes, cancer and asthma.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, describes compounding pharmacies’ efforts in tackling the tirzepatide shortage, and dispels the notion that commercialized and compounded drugs are competing with one another.
CVS Caremark, Express Scripts, OptumRx made more than $7.3 billion in revenue, with markups as high as thousands of percent.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Donald Prentiss, founder and CEO, Qualthera, comments on the role that compounding pharmacies play in the pharmaceutical supply chain from a macro perspective.
Cryoport's business unit, Cryogene, will be tasked with helping to foster the growth of Moffitt’s cell and gene therapy efforts.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, comments on how personalization could play a role in the future development of eSampling platforms.
The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, shares his inspiration behind designing SampleHub.
The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.
The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments.
The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, describes the progression of the sample distribution process.
